Holen Sie sich die Stockscreener-App
30.93
2.15%
0.65
Vorhandelsmarkt:
31.16
0.23
+0.74%
Schlusskurs vom Vortag:
$30.28
Offen:
$30.41
24-Stunden-Volumen:
949.15K
Relative Volume:
1.08
Marktkapitalisierung:
$12.83B
Einnahmen:
$5.81B
Nettoeinkommen (Verlust:
$412.00M
KGV:
32.90
EPS:
0.94
Netto-Cashflow:
-
1W Leistung:
+5.46%
1M Leistung:
+7.28%
6M Leistung:
+22.59%
1J Leistung:
+9.10%
1-Tages-Spanne:
$30.40
$30.96
1-Wochen-Bereich:
$29.27
$30.96
52-Wochen-Spanne:
$23.69
$31.72
Smith Nephew Plc Adr Stock (SNN) Company Profile
Firmenname
Smith Nephew Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
30.93 | 12.83B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-03-12 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-06 | Herabstufung | Berenberg | Buy → Hold |
| 2024-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-07-24 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-28 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-11-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-10-31 | Hochstufung | HSBC Securities | Hold → Buy |
| 2023-10-13 | Eingeleitet | Stifel | Hold |
| 2023-08-08 | Hochstufung | UBS | Sell → Neutral |
| 2023-04-27 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | Eingeleitet | Citigroup | Buy |
| 2022-11-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-07-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-04 | Hochstufung | Redburn | Sell → Neutral |
| 2021-06-09 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | Eingeleitet | Barclays | Overweight |
| 2020-07-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-21 | Eingeleitet | Citigroup | Buy |
| 2019-11-12 | Eingeleitet | Bernstein | Outperform |
| 2019-07-23 | Hochstufung | Berenberg | Hold → Buy |
| 2019-02-08 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-27 | Herabstufung | Goldman | Buy → Neutral |
| 2017-01-19 | Eingeleitet | HSBC Securities | Hold |
| 2016-12-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | Herabstufung | Berenberg | Buy → Hold |
| 2016-02-26 | Eingeleitet | Cantor Fitzgerald | Hold |
Alle ansehen
Smith Nephew Plc Adr Aktie (SNN) Neueste Nachrichten
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Bank of New York Mellon Corp - Defense World
$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery | MarketsandMarkets™ - GlobeNewswire Inc.
SNN’s 2023 Market Dance: Up 12.53% – Time to Invest? - investchronicle.com
Bessemer Group Inc. Purchases 1,701 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) - Defense World
Smith & Nephew (LON:SN) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Smith & Nephew appoints new Non-Executive Director - Investing.com
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹ - The Globe and Mail
Smith & Nephew plc ADR [SNN] Investment Appeal on the Rise - knoxdaily.com
TRI (Thomson-Reuters Corp) may reap gains as insiders became active recently - knoxdaily.com
Glaukos Corporation (GKOS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Smith+Nephew reports solid Q1 2025 growth - Investing.com
Earnings call transcript: Smith & Nephew Q1 2025 sees steady growth and innovation - Investing.com
AN Stock Sees Surge of Approximately 3.05% in Last Five Days - knoxdaily.com
Smith+Nephew schedules Q1 2025 trading report release - Investing.com
UBS cuts Smith & Nephew stock rating to Neutral, sets GBP1.25 target - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
FTSE 100 up; Smith & Nephew surges; BAE gets UK defence boost - Investing.com UK
SNN (Smith & Nephew plc ADR) may reap gains as insiders became active recently - Knox Daily
Wound Closure Market Size to Hit USD 26.63 Billion by 2032, Growing at a CAGR of 6.47% - GlobeNewswire Inc.
Goldman Downgrades Riskified Ltd (RSKD) to a Sell from a Neutral - Knox Daily
Smith+Nephew to announce 2024 full year results February 25 - Investing.com
Smith+Nephew appoints new Non-Executive Director - Investing.com
Smith & Nephew Sees Challenges in China Market - Morningstar
Smith+Nephew launches new Legion knee system - Mass Device
The Best Healthcare Stocks to Buy - Morningstar
China Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
Japan Surgical Navigation Systems Market Size & Outlook, 2030 - Grand View Research
Smith+Nephew launches Total Ankle patient-matched guides - Mass Device
Europe First Aid Market Size & Outlook, 2023-2030 - Grand View Research
Smith+Nephew launches pre-op planning tech for surgical robotics - Mass Device
Healthcare Sector - Morningstar
7 Robotic Surgery Stocks to Buy for the Future of Healthcare - Yahoo Finance
Smith+Nephew sales are up 7% as 12-point plan progresses - Mass Device
Smith+Nephew unveils expanded sports medicine portfolio - Mass Device
Study backs Smith+Nephew Regeneten bioinductive rotator cuff implant - Mass Device
Weekly Upgrades and Downgrades - Yahoo Finance
Validea Detailed Fundamental AnalysisSNN - Nasdaq
Zimmer Biomet Holdings Inc. stock outperforms market on strong trading day - MarketWatch
Zimmer Biomet Holdings Inc. stock falls Thursday, underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Monday, outperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Friday, still underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock falls Tuesday, underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Tuesday, outperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock outperforms market despite losses on the day - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Finanzdaten der Smith Nephew Plc Adr-Aktie (SNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):